Entities / Company
Atossa Therapeutics (United States).
company in Seattle, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 21
What's happening
Gone quiet
No new reports in 90+ days-
Trump pledged to unleash American oil and gas, while financial analysis highlighted cash burn and runway for businesses.Some support2 reports
-
Atossa Therapeutics could benefit from Trump-era tariffs and received analyst attention regarding its strategic moves.Speculative1 report
-
Atossa Therapeutics received positive feedback from the FDA regarding its drug candidate, (Z)-Endoxifen.Some support2 reports
-
On August 29, 2025, it was reported that Steven Quay is CEO of Atossa Therapeutics, Mark Smith is CEO of NioCorp, and the Elk Creek Project is located in Nebraska.Some support4 reports
No events began in the chosen period. Widen it, or reset.
Around Atossa Therapeutics (United States) this week
News at the entities that move Atossa Therapeutics (United States) most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Atossa Therapeutics (United States)
-
Seattle Shared contextStatue buyers are considering both Portland and Seattle as potential locations for a new monument.Moves Atossa Therapeutics (United States)
Connections
The 3 strongest of 21, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Steven Quay Structural
Steven Quay holds executive roles, including CEO and President, at Atossa Therapeutics.
-
FDA Structural
Atossa Therapeutics relies on the FDA for regulatory feedback and approval to advance its indications.
-
Seattle Shared context
Atossa Therapeutics is located in Seattle, using the city as a backdrop for corporate announcements.
History
Events by the month they beganJune 2026
4 events- Trump pledged to unleash American oil and gas, while financial analysis highlighted cash burn and runway for businesses.
- Atossa Therapeutics could benefit from Trump-era tariffs and received analyst attention regarding its strategic moves.
- Atossa Therapeutics received positive feedback from the FDA regarding its drug candidate, (Z)-Endoxifen.
- On August 29, 2025, it was reported that Steven Quay is CEO of Atossa Therapeutics, Mark Smith is CEO of NioCorp, and the Elk Creek Project is located in Nebraska.